Saillant Therapeutics B.V. is established in 2018 by Dr. Hamid el Azzouzi and Dr. Ad van Gorp. Recently joined by Dr. Joost van Bree as CEO, the team leverages its expertise in preclinical drug development to further validate and develop the promising therapeutic strategy of the ST-01 platform against acute ischemic stroke, heart failure (HF) and Alzheimer’s disease.
Saillant Therapeutics is an innovative biotechnology start-up that develops promising small molecule-based therapies. Saillant Therapeutics has a product pipeline covering novel compounds of which three therapeutic leads were selected. To date, seed financing has enabled the preclinical development and validation of the ST-01 analogs. It is the ambition of Saillant to advance its ST-01 platform also towards a variety of applications, resulting in at least one lead drug candidate reaching the clinic before the end of 2022.
For more information about Saillant Therapeutics, visit their website.